NewBiologix
NewBiologix is a Swiss biotech company dedicated to advancing gene and cell therapy manufacturing through innovative DNA integration platforms and engineered cell lines. They develop advanced cell lines and platforms to produce safer, more reliable, and cost-effective viral vectors, particularly rAAV, to accelerate the development and accessibility of gene therapies. Their mission is to help biopharmaceutical companies create transformative therapies faster, safer, and at scale, ultimately shaping the future of patient health.
Industries
Nr. of Employees
small (1-50)
NewBiologix
Route de la Corniche 6-8, Serine building 1066 Epalinges, Switzerland
Products
Engineered HEK293 suspension host cell line for rAAV production
A clonal, characterized suspension HEK293-derived host cell line engineered for improved transfection efficiency, genomic stability, high-density culture and enhanced rAAV titers across serotypes; provided under license for research and manufacturing use.
DNA integration platform for precision genome engineering
A platform combining computational design and experimental workflows for site-directed integration and advanced engineering of human and mammalian cell lines, intended to enable reproducible, stable transgene insertion.
Engineered HEK293 suspension host cell line for rAAV production
A clonal, characterized suspension HEK293-derived host cell line engineered for improved transfection efficiency, genomic stability, high-density culture and enhanced rAAV titers across serotypes; provided under license for research and manufacturing use.
DNA integration platform for precision genome engineering
A platform combining computational design and experimental workflows for site-directed integration and advanced engineering of human and mammalian cell lines, intended to enable reproducible, stable transgene insertion.
Services
Parallel candidate screening, production (transient or using engineered host cell lines), purification, and analytical characterization of rAAV candidates with data packages suitable for development and regulatory review.
End-to-end sequencing services including optimized sample preparation, short- and long-read sequencing, optical mapping, and custom bioinformatics analysis for cell-line characterization, vector sequencing and other genomic projects.
Commercial licensing of characterized mammalian host cell lines and technical support for transfer and deployment at partner laboratories and manufacturing sites.
Parallel candidate screening, production (transient or using engineered host cell lines), purification, and analytical characterization of rAAV candidates with data packages suitable for development and regulatory review.
End-to-end sequencing services including optimized sample preparation, short- and long-read sequencing, optical mapping, and custom bioinformatics analysis for cell-line characterization, vector sequencing and other genomic projects.
Commercial licensing of characterized mammalian host cell lines and technical support for transfer and deployment at partner laboratories and manufacturing sites.
Expertise Areas
- Cell line engineering for viral vector production
- rAAV production process development and scale-up
- Genomic sequencing and optical mapping for characterization
- Bioinformatics and regulatory-grade genomic reporting
Key Technologies
- Short-read next-generation sequencing
- Long-read sequencing
- Optical genome mapping
- Automated multi-dimensional digital PCR
News & Updates
Participation in a conference focused on gene and cell therapy development.
Presentation of two abstracts on innovative technologies for gene and cell therapy manufacturing.
Recognition of Igor Fisch and Nicolas Mermod with the BioAlps Industry Award.
Publication of a white paper on advanced analytical tools for rAAV characterization.
Secured $50 million in Series A funding to develop novel technology platforms.
Launched a U.S. subsidiary and appointed David Kelly as Business Development Manager.
Participation in a conference focused on gene and cell therapy development.
Presentation of two abstracts on innovative technologies for gene and cell therapy manufacturing.
Recognition of Igor Fisch and Nicolas Mermod with the BioAlps Industry Award.
Publication of a white paper on advanced analytical tools for rAAV characterization.
Secured $50 million in Series A funding to develop novel technology platforms.
Launched a U.S. subsidiary and appointed David Kelly as Business Development Manager.